East Street bridge near Mingo to be replaced for $806K
Mar. 9—Jasper County has hired a contractor to replace the bridge it shares with the City of Mingo. The county board of supervisors voted 3-0 this past week to award the contract to Peterson Contractors, Inc. for more than $806,000. The week before the county formed an agreement with Mingo to share responsibilities for the project.
County Engineer Michael Frietsch presented the bids to supervisors during their March 4 meeting. Bridge F04 is located along East Street near Mingo, and it crosses a small natural stream. The west right-of-way is under the City of Mingo's jurisdiction and the remainder is in Jasper County territory.
"The current bridge is one of those monolithic, poured concrete type structures," Frietsch said. "Its life estimate was about six years in 2023. The City of Mingo went and put in for City Bridge Funds and was granted $1.5 million in City Bridge Funding for this. We just did the 28E agreement with Mingo last week."
Five bids were received by the Iowa Department of Transportation. Petersen Contractors submitted the low bid of $806,718.40.
Jasper Construction Services, Inc. submitted a bid of more than $876,000; Herberger Construction Co., Inc. submitted a bid of more than $890,000; Manatt's Inc./Cunningham-Reis submitted a bid of more than $901,000; and Godberen-Smith Construction Co. submitted a more than $1.04 million bid.
Initial construction costs were thought to be $900,000, so the bid from Petersen Contractors is well below that original estimate. Frietsch said the late start date for the project is June 9, and there are 105 working days scheduled. Frietsch said the new bridge will be an 80-foot continuous concrete slab structure.
"It's not going to take that long to build," he said. "It's not a very big bridge. East Street is not going to be a hard road to close and divert traffic around."
Supervisor Brandon Talsma added, "You say that until you close it."
"I know. Famous last words. I know."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Iovance Biotherapeutics to Present at Upcoming Conference
SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference: Goldman Sachs Global Healthcare ConferenceFireside Chat: June 11, 2025 at 1:20 p.m. ETMiami, FL The live and archived webcasts will be available at About Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit Amtagvi ® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. Forward-Looking Statements Certain matters discussed in this press release are 'forward-looking statements' of Iovance Biotherapeutics, Inc. (hereinafter referred to as the 'Company,' 'we,' 'us,' or 'our') within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Without limiting the foregoing, we may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'forecast,' 'guidance,' 'outlook,' 'may,' 'can,' 'could,' 'might,' 'will,' 'should,' or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ('FDA') approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ('EMA') approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues may not continue to serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global pandemic; the effects of global and domestic geopolitical factors; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates. CONTACTS InvestorsIR@ ext. 150 MediaPR@ 650-260-7120 ext. 150Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Itron Publishes 2024 Corporate Sustainability Report
Advances Emissions Goals, Completes Double Materiality Assessment and Highlights Positive Customer Impact LIBERTY LAKE, Wash., June 10, 2025 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, today released its 2024 Corporate Sustainability Report. The report details Itron's environmental, social and governance (ESG) strategy and highlights how the company is empowering cities and utilities to boost efficiency, reduce emissions and build climate-resilient communities equipped to tackle a range of challenges including resource scarcity and infrastructure strain. 'At Itron, sustainability is a responsibility we embrace every day,' said Tom Deitrich, president and CEO of Itron. 'This year, Itron completed our first enterprise-wide double materiality assessment, furthering our commitment to ensure our sustainability priorities are aligned with stakeholder expectations and regulatory requirements. Just as importantly, our solutions continued to help customers reduce their own environmental impact. We remain deeply committed to creating lasting, positive change for our business, our communities and the planet.' Key areas of progress highlighted in the 2024 Corporate Sustainability Report include: Double Materiality Assessment: Itron completed the company's first Double Materiality Assessment (DMA) in 2024. The assessment included a multiphase approach to evaluate sustainability topics through both impact and financial materiality lenses. This exercise reinforces our commitment to stakeholder engagement and helps ensure our sustainability strategy is aligned with our business priorities and future regulatory requirements. Providing Sustainable Solutions: Itron's grid edge intelligence and smart city solutions continue to help customers advance their sustainability initiatives, reduce emissions and enhance customer engagement. In 2024, Itron solutions helped customers avoid more emissions than ever before with 7.5 million metric tons of greenhouse gas emissions avoided. These reductions were driven by improved operational efficiency and increased consumer engagement. Improving Our Environmental Impact: In 2024, Itron strengthened its sustainability program through key operational milestones. Itron achieved 100% ISO 14001 certification across all manufacturing facilities and maintained impeccable safety performance. Itron has reduced its Scope 1 and 2 emissions by over 50% since 2019. Supporting Our People and Communities: Itron continued to prioritize a people-first culture in 2024, earning recognition from Newsweek and U.S. News & World Report as one of America's Greatest Workplaces. In a company-led survey, nearly 95% of employees expressed their intent to stay with the company. Itron expanded its global inclusion efforts, strengthened leadership development programs and launched early-career and apprenticeship initiatives. The company also invested over $1 million in corporate philanthropy, educational outreach and volunteerism, reinforcing Itron's role as a responsible employer and a meaningful community partner. Operating with Integrity: Ethical conduct remains central to Itron's operation. In 2024, 100% of employees completed the Code of Conduct training, and nearly 90% of the Board remained independent, ensuring strong oversight. The company also earned recognition from MSCI and Sustainalytics for maintaining a low-risk ESG profile, demonstrating Itron's values-driven leadership and growing trust among stakeholders. ESG credibility remained strong, with an 'AA' MSCI rating and a 'Low Risk' designation from Sustainalytics. Itron's 2024 report underscores its continued leadership in responsible business practices and climate action. With oversight from its board of directors and active engagement across the organization, Itron's ESG strategy remains embedded in its operations. The full 2024 Corporate Sustainability Report is available for download at About Itron Itron is transforming how the world manages energy, water and city services. Our trusted intelligent infrastructure solutions help utilities and cities improve efficiency, build resilience and deliver safe, reliable and affordable service. With edge intelligence, we connect people, data insights and devices so communities can better manage the essential resources they rely on to live and thrive. Join us as we create a more resourceful world: Itron® and the Itron logo are registered trademarks of Itron, Inc. in the United States and other countries and regions. All third-party trademarks are property of their respective owners, and any usage herein does not suggest or imply any relationship between Itron and the third party unless expressly stated. Additional Resources LinkedIn: X: Newsroom: Blog: Media Contact:Alison MallahanSenior Manager, Corporate Communications(509) 891-3802PR@ Investor Contact:Paul VincentVice President, Investor Relations512-560-1172Investors@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Azitra, Inc. Announces Presentation at the 2025 BIO International Convention
BRANFORD, Conn., June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that the company will present at the BIO International Convention being held June 16-19, 2025, in Boston, Massachusetts. The presentation will highlight recent updates and progress in Azitra's pipeline, including ATR-12, currently in a Phase 1b clinical trial in adult patients with Netherton syndrome and ATR-04, in development for the treatment of moderate to severe EGFRi-associated dermal toxicity in adults. Details of the presentation are as follows: Event: 2025 BIO International Convention Date and Time: Tuesday, June 17 at 12:00 PM, ET Location: Boston Convention & Exhibition Center, Room 154 Presenter: Travis Whitfill PhD MPH, Cofounder and Chief Operating Officer During the conference, Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones. About Azitra, Inc. Azitra, Inc. is a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology. The Company's lead program, ATR-12, uses an engineered strain of S. epidermidis designed to treat Netherton syndrome, a rare, chronic skin disease with no approved treatment options. Netherton syndrome may be fatal in infancy with those living beyond a year having profound lifelong challenges. The ATR-12 program includes a Phase 1b clinical trial in adult Netherton syndrome patients. ATR-04, Azitra's additional advanced program, utilizes another engineered strain of S. epidermidis for the treatment of EGFR inhibitor ("EGFRi") associated rash. Azitra has received Fast Track designation from the FDA for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products that includes a microbial library comprised of approximately 1,500 bacterial strains. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the library of strains for drug like molecules. For more information, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will," and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, the initiation of dosing in the Phase 1/2 clinical trial for our ATR-04 program, and statements about our clinical and preclinical programs, and corporate and clinical/preclinical strategies. Any forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to that we may fail to present this abstract detailing the Phase 1/2 clinical trial or, if we are able to do so, that the abstract will be favorably received; we may experience delays in the dosing the first patient in this Phase 1/2 trial; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property crucial to our success; we may not be able to attract and retain key employees and qualified personnel; earlier study results may not be predictive of later stage study outcomes; and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra's programs and operations are described or incorporated by reference in our annual report on Form 10-K filed with the SEC on February 24, 2025. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Norman StaskeyChief Financial Officerstaskey@ Investor Relations Tiberend Strategic Advisors, Nugent205-566-3026jnugent@ Media Relations Tiberend Strategic Advisors, McDonald646-577-8520cmcdonald@ View original content to download multimedia: SOURCE Azitra, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
